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The term "burden of proof" has important 
medical and legal implications. In a legal proceeding 
the side with the burden of proof has the responsi- 
bility of proving the correctness of their allegation. 
The side without he burden of proof does not have 
to prove anything. In science in general and in 
medicine in particular, the individual proposing 
Something new clearly has the burden of proof to 
establish beyond a reasonable doubt the correctness 
of the position. The remainder of the scientific 
community, or medical community in this case, does 
not have to prove anything. Specifically, it is not the 
responsibility of the medical community to prove 
that a new treatment is inferior or bad; rather, it is the 
responsibility of the proponent to prove that it is 
superior to existing treatments, or at the very least, 
comparable. 
Have proponents of interventional vascular tech- 
nologies discharged the burden of proof in establish- 
ing the efficacy of these procedures? I submit that 
they have not, and herein ties a serious problem 
presently facing the entire vascular community in- 
cluding surgeons, internists, and radiologists. We all 
know that anecdotal claims for the efficacy of 
endovascular procedures have been with us since the 
mid-1960s. A widely recognized shortcoming of Dr. 
Charles Dotter, with whom I worked closely for 10 
years, was his consistent failure to produce any 
scientifically credible evidence of the efficacy of his 
procedures as determined by properly conducted 
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cohort studies. This failure has been repeated and 
amplified by subsequent generations of intervention- 
alists. We have been inundated during the past 25 
years with a multitude of anecdotes. This quarter 
century of anecdotal reporting has established only 
that interventional procedures occasionally succeed 
and sometimes produce dramatic results. Clearly this 
is not the question. The important questions are how 
often do these procedures succeed, how often do they 
cause complications, what is their relative cost, and 
what is their overall therapeutic value in comparison 
with well-performed vascular surgical procedures? 
As long as interventional procedures were more 
or less a novelty, I was amused by them. However, 
they have become much more than a novelty. 
Currently they are actively competing for diminish- 
ing health care funding, and of great concern to me 
is the suggestion that we devote precious portions of 
vascular residency training to the acquisition of skills 
in interventional techniques. In my opinion neither 
of these should come to pass until interventional 
proponents discharge the burden of proof in estab- 
fishing the effectiveness of their procedures. 
Let us consider for a moment he manner in 
which the validity of a scientific position is estab- 
fished. Dr. David Sackett of the Department of 
Clinical Epidemiology at McMaster University has 
succinctly defined the levels of evidence used in 
establishing the scientific validity of a position.1 Level 
1 evidence, the best, is randomized trials with low 
false-positive and low false-negative errors. Level 2 
evidence is randomized trials with high false-positive 
or false-negative errors, Level 3 evidence is nonran- 
domized, concurrent cohort comparisons, Level 4 is 
nonrandomized, historic cohort comparisons, and 
Level 5 is case series only without controls, or in 
other words, anecdotal reports. Historically both 
vascular surgery and interventional literature were 
filled almost exclusively with Level 5 data, that is, 
anecdotal evidence only. Vascular surgeons, to their 
credit, have made a concerted effort in the past 10 
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Table I. Apologia accompanying a recent 
interventional publication describing a
patient cohort 
"Because it was not possible to obtain the anlde-brachial in- 
dex systematically in all of our patients, the criteria used to 
define failure of PTA were the need for surgical revascular- 
ization or the need for major amputation." 
From Matsi PJ, Manninen HI, Suhonen MT, Pirinen AE, 
Soimakallio S. Chronic critical ower-limb ischemia: prospective 
trial of angioplasty with 1-36 months follow-up. Radiology 1993; 
188:381-7. 
years to improve this situation. Level 3 and 4 
evidence has become the standard for patient cohort 
reporting in our journal, and Level 5 evidence has 
become distinctly less frequent. Unfortunately, these 
improvements have not been reflected in the inter- 
ventional literature. 
The interventionalists themselves have fully rec- 
ognized the unacceptable l vel of evidence in their 
publications. In May of 1991 the newly founded 
Journal of Vascular and Interventional Radiology 
adopted scientific reporting standards quite similar to 
those recommended by the Ad Hoc Committee on 
Reporting Standards of the Joint Councils of the 
vascular surgical societies. 2,3 
To determine the influence this policy has had on 
interventional publications in radiology journals, I
have reviewed all interventional cohort studies re- 
ported in the radiology journals, Radiology and the 
Journal of Vascular and Interventional Radiology, for 
the past 27 months. I have evaluated the interven- 
tional cohort reports both by the reporting standards 
of the Society for Interventional Radiology and by 
Sackett's rules of evidence. I have sadly concluded 
that only four interventional cohort articles met 
objective reporting standards during this 27-month 
reporting period. 
When asked about the need for scientific report- 
ing, every academic interventional radiologist I have
talked with has completely supported the concept. 
However, they most assuredly are not practicing 
what they preach. A typical apologia from a recent 
angioplasty publication is seen in Table 1. 4 In the 
absence of leg bypass or amputation, the angioplasty 
was reported as successful. The absurdity of this 
position is apparent, but it obviously was accepted by 
this prestigious journal. 
I have been able to find only two prospective 
randomized studies pertaining to interventional 
therapy. One was a fascinating study by Creasy and 
Collin, from Oxford University, published in the 
European Journal of Vascular Surgery. s In this study 36 
patients with significant claudication deemed accept- 
able for balloon angioplasty of the superficial femoral 
Table II. Ineffective procedures used in 








artery were prospectively randomized to angioplasty 
or nonoperative treatment consisting of exercise 
therapy. At the end of 12 months the patients who 
were randomized to exercise therapy were walking 
three times farther than those who underwent 
successful angioplasty. The other prospective ran- 
domized study was the much quoted Veterans 
Administration study, in which patients with claudi- 
cation deemed appropriate for angioplasty were 
prospectively randomized to surgical procedures or 
angioplasty. 6,7 If the initial failures were ignored, the 
angioplasty and the surgical groups appeared to 
perform about the same. Unfortunately, several 
major flaws mar this study. In the first place, when 
analyzed by intention to treat, the accepted standard, 
the patients who underwent surgical procedures 
fared better. In addition, a disappointing 40% of 
patients who underwent leg bypass procedures re- 
ceived prosthetic limb bypasses. The 3-year femo- 
ropopliteal graft patency of 66% is indeed disap- 
pointing. Clearly these are not state-of-the-art vascu- 
lar surgical results and must be interpreted 
accordingly. 
In my opinion the only tenable conclusion at 
present is that we have no substantive cohort data 
objectively establishing the role of interventional 
therapy in any area of arterial or venous disease 
treatment. Anecdotes abound, hard data are scarce. 
Do not be deceived by the potential of doing harm by 
basing therapeutic decisions on anecdotal data. Con- 
sider the widely practiced treatments listed in Table 
II. All were based on anecdotal data, and all were 
eventually recognized as ineffective. Each cost bil- 
lions of dollars and subjected countless patients to 
ineffective treatment. 
At present it is my best judgment that optimally 
selected common iliac stenoses dilated by a skilled 
interventionalist probably produce a 3-year primary 
patency of 60% to 70%, which is acceptable but 
inferior to that of well-performed operations. Angio- 
plasty of highly selected superficial femoral esions, 
which most surgeons would recommend for nonop- 
erative therapy, results in a 1-year patency of 50% to 
60%. Leg bypass urgical procedures in large cohorts 
by Leather et al., 8 Bergaminl et al.,9 Anderson et al.,10 
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US, 11 and others produce a 1-year patency of about 
90%, basically twice as good as highly selected 
angioplasties in patients with minimal disease. It is 
clear that the cost of interventional procedures i
comparable to the cost of surgical procedures. The 
only studies addressing this finding in recent years, 
the Dartmouth study n and the recent Hunink study 
from Brigham, 13 have established the comparability 
of cost. Few dispute that the complications and 
mortality rates are nearly equal between surgical 
procedures and angioplasty. 
Thus the acceptance orrejection of angioplasty as 
valid therapy should turn exclusively on the interval 
patency of the procedure compared with that of 
comparable surgical therapy. Although objective 
information is scarce, it is my impression that 
angioplasty produces patency results at best about 
50% to 60% that of well-performed vascular surgical 
procedures with similar costs and complications. 
A timely question is how should vascular sur- 
geons respond to angioplasty in its current unproven 
state? I submit hat in the absence of proof of efficacy, 
all interventional procedures must be regarded as 
experimental. Until and unless interventionalists 
present us with properly conducted cohort studies 
with appropriate study design clearly establishing 
efficacy, we must not regard interventional treat- 
ments as proven therapy for our patients. In our 
current state of ignorance, vascular surgeons have no 
idea whether they are making the correct decision 
when they refer their patients for angioplasty orsome 
variant hereof. 
I sincerely hope the health care funding agencies 
will carefully consider the unproven status of inter- 
ventional procedures when allocating health care 
resources. I note with pleasure that the Food and 
Drug Administration has adopted a recent policy of 
much more critical assessment of class III medical 
devices. Prospective randomized study comparisons 
with alternate therapies will become the standard for 
approval of class III devices, and the issues of clinical 
utility, safety, and efficacy will be addressed. 
Let me make it quite clear that I am not opposed 
to research in the area 'of interventional therapy. In 
fact, by demanding objective proof of efficacy, I may 
be one of its more important advocates. I sincerely 
hope the academic interventional leaders currently 
presenting dozens of anecdotal talks in a plethora of 
interventional symposia nnually will combine their 
resources to produce cohort studies with proper 
randomization and controls to establish scientific 
credibility. Vascular surgeons must stand ready to 
cooperate in properly designed prospective studies. 
If the interventionalists do not follow these 
procedures, their discipline will be fatally flawed by 
the permanent absence of a credible scientific base 
and will ultimately fail to achieve the standing to 
which it may be entitled. Interventionalists had best 
realize that the salad days of anecdotal reporting are 
over. Discharge your burden of proof and scientifi- 
cally establish the credibility of your procedures, or 
prepare for an uncertain future in which you may fare 
surprisingly poorly. I submit it will be far more 
difficult to deceive finance committees of health 
maintenance organizations, the Health Care Financ- 
ing Administration, and the Food and Drug Admin- 
istration than it has been to attract an unending 
stream of gullible patients eternally seeking the fabled 
but to date illusory free lunch. 
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